The GLP-1 Conundrum
Tuesday, May 21, 2024 (12:00 PM - 1:00 PM) (CDT)
Description
The rapid proliferation in the use of glucagon-like peptide 1 (GLP-1) agonists for the control of type 2 diabetes (Ozempic) and weight loss (Wegovy) has created a conundrum for employers. There is no doubt (GLP-1’s are the most effective drugs for weight loss on the market. Wegovy is also extremely effective at improving the lives of those with pre-existing cardiovascular disease. In early March the FDA approved the use of Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with heart disease with obesity or overweight.
Employers are confused and in need to guidance. This new class of expensive “miracle” drugs is a top concern for employers as they sort through options for their inclusion or exclusion from their formulary. Register today for a 1-hour employer-only webinar on May 21 from 12:00 pm - 1:00 pm. Attendees can choose to remain in the webinar after 1:00 pm and ask questions of the panelists.
The panel will include the perspective of a GLP-1 manufacturer, an employer purchaser and an actuarial consultant.
Kathy Giammona, Pharm. D, Medical Account Director, Novo Nordisk
Michelle Buckner, U.S Benefits Director, KBR, Inc
A.J Ally R.PH, MBA, Principal & Pharmacy Management Consultant, Milliman